Takeaways: Siliq’s listing under Alberta’s public drug plan expands brodalumab’s public coverage across Canada, leaving only British Columbia without provincial reimbursement and improving...
Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
